Work on hydroxychloroquine delayed promising studies of convalescent plasma

Posted on AllSides August 6th, 2020
From The Left
coronavirus, coronavirus treatments, hydroxychloroquine, convalescent plasma

Robust scientific studies on convalescent plasma, a potentially promising COVID-19 treatment, have gotten off to a slow start in the U.S., in part because some researchers were more focused on enrolling their sickest patients in other trials, including some for hydroxychloroquine.

"You always have that hindsight and say, oh man, we should have put our efforts into something else," said Dr. Todd Rice, an associate professor of medicine at Vanderbilt University Medical Center.

Early on in the pandemic, Vanderbilt was involved in multiple clinical trials, including those on remdesivir and...

Read full story

NBC News (Online)

AllSides Media Bias Rating: Lean Left
AllSides Media Bias Rating: Lean Left
See full bias rating for NBC News (Online)
Learn about media bias

More News about Coronavirus from the Left, Center and Right

From the Left

From the Center

From the Right